BR112012017188A8 - composto agonista de mglu2, sua composição farmacêutica e seu uso - Google Patents
composto agonista de mglu2, sua composição farmacêutica e seu usoInfo
- Publication number
- BR112012017188A8 BR112012017188A8 BR112012017188A BR112012017188A BR112012017188A8 BR 112012017188 A8 BR112012017188 A8 BR 112012017188A8 BR 112012017188 A BR112012017188 A BR 112012017188A BR 112012017188 A BR112012017188 A BR 112012017188A BR 112012017188 A8 BR112012017188 A8 BR 112012017188A8
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- agonist compound
- mglu2
- mglu2 agonist
- agonists
- Prior art date
Links
- -1 mglu2 agonist compound Chemical class 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000000556 agonist Substances 0.000 abstract 3
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 208000011688 Generalised anxiety disease Diseases 0.000 abstract 1
- 208000029364 generalized anxiety disease Diseases 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
patente de invenção: "agonistas de mglu2". a presente invenção refere-se a novos agonistas de mglu2 úteis no tratamento de distúrbios bipolar, esquizofrenia, depressão e distúrbio de ansiedade generalizada. os novos agonistas são representados pela fórmula
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09382290 | 2009-12-21 | ||
EP09382290.6 | 2009-12-21 | ||
US30523910P | 2010-02-17 | 2010-02-17 | |
US61/305,239 | 2010-02-17 | ||
PCT/US2010/060371 WO2011084437A1 (en) | 2009-12-21 | 2010-12-15 | Mglu2 agonists |
Publications (3)
Publication Number | Publication Date |
---|---|
BR112012017188A2 BR112012017188A2 (pt) | 2016-03-22 |
BR112012017188A8 true BR112012017188A8 (pt) | 2016-10-04 |
BR112012017188B1 BR112012017188B1 (pt) | 2021-06-22 |
Family
ID=42026702
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012017188-7A BR112012017188B1 (pt) | 2009-12-21 | 2010-12-15 | Agonistas de glutamato metabotrópico (mglu2), e composição farmacêutica |
Country Status (35)
Country | Link |
---|---|
US (1) | US8318184B2 (pt) |
EP (1) | EP2516406B1 (pt) |
JP (1) | JP5779190B2 (pt) |
KR (1) | KR101395356B1 (pt) |
CN (1) | CN102695701B (pt) |
AR (1) | AR079343A1 (pt) |
AU (1) | AU2010340039B2 (pt) |
BR (1) | BR112012017188B1 (pt) |
CA (1) | CA2784667C (pt) |
CR (1) | CR20120322A (pt) |
CY (1) | CY1114880T1 (pt) |
DK (1) | DK2516406T3 (pt) |
DO (1) | DOP2012000173A (pt) |
EA (1) | EA020229B1 (pt) |
EC (1) | ECSP12011989A (pt) |
ES (1) | ES2435651T3 (pt) |
HK (1) | HK1171228A1 (pt) |
HN (1) | HN2012001160A (pt) |
HR (1) | HRP20131052T1 (pt) |
IL (1) | IL220011A (pt) |
JO (1) | JO2978B1 (pt) |
MA (1) | MA33824B1 (pt) |
MX (1) | MX2012007332A (pt) |
MY (1) | MY160618A (pt) |
NZ (1) | NZ600305A (pt) |
PE (1) | PE20121688A1 (pt) |
PL (1) | PL2516406T3 (pt) |
PT (1) | PT2516406E (pt) |
RS (1) | RS53063B (pt) |
SG (1) | SG181836A1 (pt) |
SI (1) | SI2516406T1 (pt) |
TN (1) | TN2012000281A1 (pt) |
TW (1) | TWI477490B (pt) |
UA (1) | UA107684C2 (pt) |
WO (1) | WO2011084437A1 (pt) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3533797B1 (en) | 2010-02-17 | 2023-12-20 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
JP5870111B2 (ja) * | 2010-11-18 | 2016-02-24 | イーライ リリー アンド カンパニー | mGluR2/3アンタゴニストとしての4−置換−3−ベンジルオキシ−ビシクロ[3.1.0]ヘキサン化合物 |
TWI520935B (zh) * | 2010-11-18 | 2016-02-11 | 美國禮來大藥廠 | 作為mGluR2/3拮抗劑之4-經取代-3-苯基磺醯基甲基-雙環[3.1.0]己烷化合物 |
HUE030171T2 (en) * | 2011-06-17 | 2017-05-29 | Lilly Co Eli | Bicyclo (3.1.0) hexane-2,6-dicarboxylic acid derivatives such as mGlu2 receptor agonists |
AR089718A1 (es) | 2012-02-01 | 2014-09-10 | Lilly Co Eli | AGONISTAS DE mGlu2/3 |
EP2919788A4 (en) | 2012-11-14 | 2016-05-25 | Univ Johns Hopkins | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SCHIZOPHRENIA |
KR20200036063A (ko) | 2014-01-21 | 2020-04-06 | 얀센 파마슈티카 엔.브이. | 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도 |
JP6629740B2 (ja) * | 2014-01-21 | 2020-01-15 | ヤンセン ファーマシューティカ エヌ.ベー. | 代謝型グルタミン酸作動性受容体サブタイプ2の正のアロステリック調節因子またはオルトステリックアゴニストを含む組み合わせ、およびそれらの使用 |
DK3277270T3 (da) | 2015-04-01 | 2021-12-06 | Akebia Therapeutics Inc | Sammensætninger og fremgangsmåder til behandling af anæmi |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5576323A (en) | 1993-12-03 | 1996-11-19 | Eli Lilly And Company | Excitatory amino acid receptor antagonists |
US5688826A (en) * | 1995-11-16 | 1997-11-18 | Eli Lilly And Company | Excitatory amino acid derivatives |
GB9605429D0 (en) * | 1995-11-16 | 1996-05-15 | Lilly Co Eli | Excitatory amino acid receptor antagonists |
ZA983930B (en) | 1997-05-14 | 1999-11-08 | Lilly Co Eli | Excitatory amino acid receptor modulators. |
WO2002055485A1 (en) * | 2001-01-11 | 2002-07-18 | Eli Lilly And Company | Prodrugs of excitatory amino acids |
CN1267407C (zh) * | 2001-01-11 | 2006-08-02 | 伊莱利利公司 | 兴奋性氨基酸前体药物 |
EP1370519A1 (en) * | 2001-02-22 | 2003-12-17 | Eli Lilly And Company | Synthetic excitatory amino acids |
AU2003232146B2 (en) | 2002-06-11 | 2009-06-18 | Eli Lilly And Company | Prodrugs of excitatory amino acids |
US7381746B2 (en) * | 2003-06-26 | 2008-06-03 | Taisho Pharmaceutical Co., Ltd. | 2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative |
JP5870111B2 (ja) * | 2010-11-18 | 2016-02-24 | イーライ リリー アンド カンパニー | mGluR2/3アンタゴニストとしての4−置換−3−ベンジルオキシ−ビシクロ[3.1.0]ヘキサン化合物 |
TWI520935B (zh) * | 2010-11-18 | 2016-02-11 | 美國禮來大藥廠 | 作為mGluR2/3拮抗劑之4-經取代-3-苯基磺醯基甲基-雙環[3.1.0]己烷化合物 |
-
2010
- 2010-12-09 JO JO2010439A patent/JO2978B1/en active
- 2010-12-09 AR ARP100104553A patent/AR079343A1/es active IP Right Grant
- 2010-12-10 TW TW099143362A patent/TWI477490B/zh active
- 2010-12-15 MX MX2012007332A patent/MX2012007332A/es active IP Right Grant
- 2010-12-15 CN CN201080058183.2A patent/CN102695701B/zh active Active
- 2010-12-15 ES ES10798419T patent/ES2435651T3/es active Active
- 2010-12-15 DK DK10798419.7T patent/DK2516406T3/da active
- 2010-12-15 US US12/968,352 patent/US8318184B2/en active Active
- 2010-12-15 RS RS20130530A patent/RS53063B/en unknown
- 2010-12-15 KR KR1020127015935A patent/KR101395356B1/ko active IP Right Grant
- 2010-12-15 JP JP2012544727A patent/JP5779190B2/ja active Active
- 2010-12-15 SG SG2012045563A patent/SG181836A1/en unknown
- 2010-12-15 PE PE2012000856A patent/PE20121688A1/es active IP Right Grant
- 2010-12-15 CA CA2784667A patent/CA2784667C/en active Active
- 2010-12-15 BR BR112012017188-7A patent/BR112012017188B1/pt active IP Right Grant
- 2010-12-15 SI SI201030387T patent/SI2516406T1/sl unknown
- 2010-12-15 PT PT107984197T patent/PT2516406E/pt unknown
- 2010-12-15 PL PL10798419T patent/PL2516406T3/pl unknown
- 2010-12-15 AU AU2010340039A patent/AU2010340039B2/en active Active
- 2010-12-15 WO PCT/US2010/060371 patent/WO2011084437A1/en active Application Filing
- 2010-12-15 UA UAA201206909A patent/UA107684C2/ru unknown
- 2010-12-15 EP EP10798419.7A patent/EP2516406B1/en active Active
- 2010-12-15 NZ NZ600305A patent/NZ600305A/en unknown
- 2010-12-15 EA EA201290558A patent/EA020229B1/ru not_active IP Right Cessation
- 2010-12-15 MY MYPI2012002794A patent/MY160618A/en unknown
-
2012
- 2012-05-24 IL IL220011A patent/IL220011A/en active IP Right Grant
- 2012-05-30 HN HN2012001160A patent/HN2012001160A/es unknown
- 2012-06-01 TN TNP2012000281A patent/TN2012000281A1/en unknown
- 2012-06-13 CR CR20120322A patent/CR20120322A/es unknown
- 2012-06-14 MA MA34967A patent/MA33824B1/fr unknown
- 2012-06-19 DO DO2012000173A patent/DOP2012000173A/es unknown
- 2012-06-20 EC ECSP12011989 patent/ECSP12011989A/es unknown
- 2012-11-23 HK HK12112042.9A patent/HK1171228A1/xx unknown
-
2013
- 2013-11-06 HR HRP20131052AT patent/HRP20131052T1/hr unknown
- 2013-11-14 CY CY20131101012T patent/CY1114880T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112012017188A8 (pt) | composto agonista de mglu2, sua composição farmacêutica e seu uso | |
SV2008003088A (es) | Nueva forma cristalina vi de la agomelatina, su procedimiento de preparacion y las composiciones farmaceuticas que la contienen | |
CR20110318A (es) | Compuestos, composición farmacéutica y métodos para utilizarse en el tratamiento de trastornos metabólicos | |
BR112015012425A2 (pt) | composto, composição farmacêutica, método e medicamento para o tratamento de doenças medicadas pela proteína parp-1 e uso do composto | |
UY32174A (es) | Nuevos heterociclos sustituidos, composiciones farmaceuticas conteniendolos, procedimientos de preparacion y aplicaciones | |
BR112016010080A8 (pt) | compostos de pirazolopirimidina, composição farmacêutica e seu uso | |
BRPI0913457A2 (pt) | "composto, composição farmacêutica, e, uso do composto" | |
EA201200918A1 (ru) | Производные пирролидин карбоновой кислоты как агонисты сопряженного с g-белком рецептора 43 (gpr43), фармацевтическая композиция и методы их использования при лечении метаболических нарушений | |
BR112014032809A2 (pt) | melhora de autofagia ou aumento de longevidade pela administração de urolitinas ou precursores das mesmas | |
EA201071169A1 (ru) | ГИДРОКСИМЕТИЛПИРРОЛИДИНЫ В КАЧЕСТВЕ АГОНИСТОВ АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ β3 | |
BR112013031405A2 (pt) | piridopirazinas substituídas como novos inibidores de syk | |
EA201100503A1 (ru) | Глюкозидные производные и их применения | |
DE602008000754D1 (de) | Tropanverbindungen | |
CL2007001784A1 (es) | Compuestos derivados de benzoxazol de formula la, su composicion farmaceutica, metodo para medir in vivo depositos de amoloide empleando dicha composicion, y uso del compuesto la para preparar un medicamento, y compuesto de formula ib, y su uso como precursor en la preparacion de un compuesto marcado. | |
BR112012007322A2 (pt) | composto de 2-piridona usados como inibidores de neutrófilo elastase | |
CR11814A (es) | Derivados de azacarbolinas, su preparacion y su utilizacion terapeutica | |
EA201070327A1 (ru) | Катехоламиновые производные и их пролекарства | |
BR112015004529A8 (pt) | alcóxi pirazóis, seu uso como ativadores de guanilato ciclase solúvel e composição farmacêutica que os compreende | |
ECSP099806A (es) | Oxazolidinonas sustituidas y su uso | |
CL2013002664A1 (es) | Compuestos derivados heterociclicos de amina; afines a receptores asociados a mina traza taar1; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento o profilaxis de la depresion, ansiedad, parkinson, trastorno bipolar, de hiperactividad con deficit atencional, relacionados con estres, y otros. | |
ATE500222T1 (de) | Benzamid- und heteroarenderivate als cetp- inhibitoren | |
UA109290C2 (uk) | Спільні кристали і солі інгібіторів ccr3 | |
BR112014012459A2 (pt) | 2h-indazóis como antagonistas do receptor de ep2 | |
BR112015004523A2 (pt) | compostos de tetraciclina | |
SG158091A1 (en) | Imidazoazepinone compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/12/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, , QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |